The deal secures rights to sevasemten, a first-in-class skeletal myosin inhibitor currently in pivotal testing for Becker muscular dystrophy and phase 2 trials for Duchenne muscular dystrophy. By integrating Edgewise’s specialized team, Servier aims to address the significant lack of approved treatments for these degenerative disorders, which cause irreversible muscle loss and severely limit mobility from a young age.

Olivier Laureau, President of Servier, described the move as a critical step toward the company’s 2030 strategic goals in rare neurology. For Edgewise, the transition provides the global infrastructure necessary to push the asset through final regulatory hurdles. The remaining $1.1 billion of the transaction is tied to future commercial and regulatory milestones, marking a major expansion of Servier’s clinical footprint in the rare disease space.